Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Does the media favor BIIB or MDGL?

In the previous week, Biogen had 20 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 24 mentions for Biogen and 4 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.80 beat Biogen's score of 0.74 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	9 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is BIIB or MDGL more profitable?

Biogen has a net margin of 15.07% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Biogen's return on equity of 14.03% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.07%	14.03%	8.32%
Madrigal Pharmaceuticals	-123.38%	-50.54%	-37.19%

Which has more volatility and risk, BIIB or MDGL?

Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, indicating that its stock price is 205% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of BIIB or MDGL?

87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.93	$1.63B	$10.13	12.59
Madrigal Pharmaceuticals	$317.38M	21.77	-$465.89M	-$18.05	-17.24

Do analysts prefer BIIB or MDGL?

Biogen presently has a consensus target price of $188.48, suggesting a potential upside of 47.83%. Madrigal Pharmaceuticals has a consensus target price of $420.63, suggesting a potential upside of 35.19%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Summary

Biogen beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.